News|Articles|March 8, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-04-06-2016
  • Volume 11
  • Issue 4

DPT and Confab Complete $10 Million Capital Investment

The investment includes facility upgrades and expansion of development capabilities.

DPT Laboratories, a contract development and manufacturing organization (CDMO) specializing in semi-solid and liquid dosage forms, and Confab, a DPT company specializing in complex solids, semi-solids, and liquids, have completed a combined $10 million capital investment.

According to a press announcement from the company, DPT invested in a new compounding suite and upgrades to production filling lines. Additional upgrades include a remodeled front office area, enhanced security, and enhancement for further GMP compliance.

Confab, based in Montreal, made an investment to increase R&D capabilities with a new laboratory, new equipment, and expansion of its R&D team. According to a press announcement, Confab will now offer pharmaceutical development capabilities including formulation development, analytical method development, and technology transfers at commercial scale.

Source: DPT 

Articles in this issue

almost 10 years ago

Fundamentals for Pharma Agility and ROI

almost 10 years ago

Specialty API Manufacturers Invest for Growth

almost 10 years ago

Identifying Relevant Crystalline Forms

almost 10 years ago

Going Global Increases API Monitoring Burden

almost 10 years ago

U.S. Representatives Question the Safety of the Heparin Supply

almost 10 years ago

Biopharmaceutical Outsourcing Continues to Grow

almost 10 years ago

CSafe Global Opens Atlanta Service Center

almost 10 years ago

Article Details New 3D Modeling and Data Extraction Technique

almost 10 years ago

CMC Biologics and IDT Biologika Collaborate on ADC Manufacturing

almost 10 years ago

Vetter Breaks Ground on New Production Facility

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!

Related Content